Shares of Voyager Therapeutics Inc (NASDAQ:VYGR) have been assigned an average rating of “Buy” from the fourteen brokerages that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $32.50.
Several brokerages have recently commented on VYGR. BTIG Research reiterated a “buy” rating and issued a $32.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $27.00 target price on shares of Voyager Therapeutics in a research report on Monday, September 10th. Chardan Capital reiterated a “hold” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday, June 21st. ValuEngine upgraded Voyager Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Finally, Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 11th.
In related news, Director James A. Geraghty purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The shares were acquired at an average price of $19.39 per share, with a total value of $58,170.00. Following the acquisition, the director now owns 76,588 shares in the company, valued at approximately $1,485,041.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Glenn Pierce purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The stock was bought at an average cost of $18.44 per share, for a total transaction of $92,200.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 11,000 shares of company stock worth $205,300. Company insiders own 33.60% of the company’s stock.
NASDAQ VYGR traded down $0.33 during mid-day trading on Friday, reaching $18.15. 3,816 shares of the company’s stock traded hands, compared to its average volume of 217,377. Voyager Therapeutics has a 1-year low of $11.54 and a 1-year high of $31.91. The firm has a market cap of $584.50 million, a PE ratio of -6.89 and a beta of 2.89.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The business had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. equities analysts anticipate that Voyager Therapeutics will post -3.19 EPS for the current year.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: Average Daily Trade Volume Explained
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.